Sector News

Moderna poaches Amgen vet as CCO, jump-starting commercial team as it rolls out COVID-19 vaccine

January 17, 2021
Life sciences

Moderna is smack in the middle of a very high-profile product launch—its COVID-19 vaccine, second to market in the U.S., but the biotech’s first-ever rollout. And now, it’s tapped veteran Amgen executive Corinne Le Goff to spearhead that effort as chief commercial officer.

Le Goff jumped to Moderna from her role as senior VP and president of Amgen’s U.S. business. A pharmacist by training, she’s credited with overseeing Amgen’s Otezla integration after the company acquired the drug from Celgene in 2019 and boosting sales of cholesterol med Repatha and migraine launch Aimovig. At Amgen six years, she also served as head of its European region responsible for 48 markets.

But her full resume reads like a Big Pharma card catalog. Before Amgen, she held leadership roles overseeing product portfolios at Roche, Sanofi, Merck & Co. and Pfizer, across a variety of therapeutic areas including oncology, neurology and immunology.

Moderna will lean on her extensive experience developing and leading global pharma teams as it moves to launch its COVID-19 vaccine—and shepherds other pipeline projects toward approval.

“Corinne is joining us at an important time as we launch our COVID-19 vaccine, prepare to start the Phase 3 study of our CMV vaccine and pivot to a commercial-stage company,” Moderna CEO Stéphane Bancel, said in a press release, adding that her impressive track record “will position Moderna well as we continue building a best-in-class commercial team.”

While Moderna created its COVID-19 mRNA-based vaccine, conducted clinical testing, submitted its vaccine to the FDA and won emergency authorizations in less than a year, the vaccine rollout and marketing is new territory. Le Goff and the commercial team will be key to that success.

Moderna debuted its first consumer campaign late last month, touting its 10 years of experience and mRNA technology as its “modern approach to medicine.”

Le Goff will start on January 19. She said she is “delighted” to join Moderna as it launches its vaccine and transforms to a commercial-stage company from R&D-focused biotech. “The Moderna technology is game-changing,” she said, “and will undoubtedly disrupt the traditional biotechnology world and in time lead to life-altering therapies.”

by Beth Snyder Bulik

Source: fiercepharma.com

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.